Herpes simplex virus (HSV) is a ubiquitous human pathogen capable of causing a variety of clinically important diseases. The role of the immune response in controlling primary and recurrent HSV infection is under investigation. HSV glycoprotein C (gC) is highly immunogenic for both humoral and cellular immune responses and consequently plays a major role in the immunobiology of infection. The central aims of this competing renewal application are (i) to develop a more complete understanding at the molecular level of the antigenic structure of gC as recognized by both antibodies and cytotoxic T lymphocytes (CTL), with an emphasis on a comparative analysis of the organization of antigenic domains and component epitopes between gC of the two serotypes and (ii) to explore the potential usefulness of gC as a subunit vaccine against virus-induced encephalitis and zosteriform lesions using the mouse as a model host. The central hypothesis to be tested is that the antigenic domains of gC-1 and gC-2 are colinear and that the predominant type-specificity exhibited by these domains is due to the presence of dissimilar amino acids within the component epitopes. The experimental strategy for defining type-specific epitope structure and organization will be to compare the reactivity of large panels of gC-1 and gC-2 specific mAbs with (i) a series of genetically engineered gC-1:gC-2 chimeric gene products and (ii) panels of wild-type and mutant synthetic peptides. The peptides will also be used to develop antibody reagents to discover new antigenic determinants and for a more detailed analysis of known antigenic sites. Correlation of the epitope mapping studies with antigenic variation among fresh clinical isolates will be sought in order to assess the stability of epitope structure and to detect genetically invariant domains. Studies of the CTL responses to HSV gC will be continued using short-term and long-term CTL clones to (i) confirm that gC of both serotypes is the major inducer and target antigen for CTLs (ii), define CTL-specific epitopes at a molecular level, and (iii) determine the extent to which the B and T cell repertoires overlap in their recognition of gC. Finally, purified gC derived with a baculovirus expression vector system in combination with synthetic peptides will be used in immunization protocols to induce protective immunity against HSV-induced neurological and peripheral lesions with emphasis on prevention of latent infection of ganglion neurons.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM034534-07
Application #
3285708
Study Section
Experimental Virology Study Section (EVR)
Project Start
1984-09-12
Project End
1992-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
7
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Tsvitov, Marianna; Frampton Jr, Arthur R; Shah, Waris A et al. (2007) Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360:477-91
Jiang, Canping; Glorioso, Joseph C; Ataai, Mohammad (2006) Presence of imidazole in loading buffer prevents formation of free radical in immobilized metal affinity chromatography and dramatically improves the recovery of herpes simplex virus type 1 gene therapy vectors. J Chromatogr A 1121:40-5
Hong, C-S; Goins, W F; Goss, J R et al. (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-79
Jiang, Canping; Ataai, Mohammad; Ozuer, Ali et al. (2006) Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng 95:48-57
Nakano, Kenji; Asano, Ryutaro; Tsumoto, Kouhei et al. (2005) Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 11:617-26
Moriuchi, Shusuke; Glorioso, Joseph C; Maruno, Motohiko et al. (2005) Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther 12:487-96
Sasaki, Katsumi; Chancellor, Michael B; Goins, William F et al. (2004) Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 53:2723-30
Niranjan, Ajay; Wolfe, Darren; Tamura, Masakazu et al. (2003) Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 8:530-42
Burton, Edward A; Hong, Chang-Sook; Glorioso, Joseph C (2003) The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells. J Virol 77:3516-30
Moriuchi, S; Wolfe, D; Tamura, M et al. (2002) Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 9:584-91

Showing the most recent 10 out of 46 publications